Tesamorelin is a synthetic analogue of growth hormone releasing hormone (GHRH); specifically a stabilized form of the endogenous GHRH(1-44) sequence with a trans 3 hexenoic acid modification that significantly extends its plasma half life compared to native GHRH. Hudson Science’s formulation supplies 20mg as a lyophilized vial, preserving peptide structural integrity and potency across storage conditions until reconstitution. Tesamorelin holds the distinction of being one of the few GHRH analogues to achieve full FDA approval, cleared for the treatment of HIV associated lipodystrophy under the brand name Egrifta. Contributing a well documented human clinical literature base that distinguishes it from most research peptide compounds.

Tesamorelin’s mechanism of action operates through selective binding to pituitary GHRH receptors, stimulating endogenous growth hormone secretion in a physiologically regulated pulsatile pattern rather than delivering exogenous growth hormone directly. This distinction is pharmacologically significant — by stimulating the pituitary’s own GH secretion rather than bypassing it, Tesamorelin preserves the natural feedback regulation of the GH/IGF-1 axis, including the somatostatin mediated suppression that prevents the continuous GH elevation associated with exogenous GH administration. This regulated stimulation mechanism has made Tesamorelin a frequently studied reference compound in research examining growth hormone secretagogue pharmacology and pituitary axis modulation.

The clinical literature on Tesamorelin is notably robust for a research peptide, with documented investigation across visceral adipose tissue reduction, IGF-1 axis modulation, cognitive function in ageing populations, and cardiovascular risk marker research. Its FDA approval history provides a regulatory documentation baseline that most GHRH analogue research compounds lack, making it a valuable reference standard in comparative growth hormone secretagogue studies examining efficacy, safety, and pituitary axis response across different stimulation mechanisms.

Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and Hudson Science’s Tesamorelin meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.

Commonly researched alongside CJC-1295 and Ipamorelin in comparative GHRH axis stimulation studies. Browse CSD’s full peptide range for complete sourcing.